HealthEquity Inc. stocks have been trading up by 3.84 percent amid strong earnings-driven optimism and expanding healthcare savings demand
What Traders Need To Know
- Record Q2 FY27 print showed 8% revenue growth, 10% net income growth, a 48% adjusted EBITDA margin, 14% HSA asset growth to nearly $38B, $108M buyback, and higher FY27 guidance.
- Q2 adjusted EPS of $1.24 versus $1.19 consensus and revenue of $350.7M versus $349.2M confirmed a clean, but modest, beat on both lines.
- Despite strong fundamentals and slightly higher longer‑term outlook, shares dropped about 14% after the report and traded over 5% lower premarket.
- FY27 revenue guidance of $1.41B–$1.42B and adjusted EPS of $4.66–$4.73 came in essentially in line with consensus, signaling steady but not explosive upside.
- RBC reiterated an Outperform rating and a $108 target, pointing to AI‑driven cost cuts, Marketplace, and Bronze plan enrollment as key growth levers into FY28.
Weekly Update Aug 24 – Aug 28, 2026: On Sunday, August 30, 2026 HealthEquity Inc. stock [NASDAQ: HQY] is trending up by 3.84%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
HealthEquity sits in a structurally advantaged niche within healthcare benefits, with a leading HSA franchise and a high‑margin, asset‑light model. Gross margin above 70% and EBITDA margin of ~35% (management reporting 48% adjusted) underscore strong operating leverage, while revenue growth of 13–14% over three and five years outpaces most healthcare services peers. Balance sheet quality is solid: net leverage is modest (debt/equity 0.48, current ratio 3.4) and cash generation is robust, with Q2 free cash flow of ~$120M versus ~$65M net income. Valuation at ~36x trailing EPS and ~6x sales embeds a growth premium, but ROE above 11%, improving ROIC, and recurring fee‑based economics justify a high‑teens to low‑20s earnings multiple on forward EPS, especially as HSA assets scale and mix shifts toward invested balances.
Technically, HQY just experienced a violent reversal: after trading up to $106.8, it gapped down to the low‑90s and is attempting a rebound toward $97. The dominant short‑term trend is now down, with an open downside gap and clear supply in the $104–107 region. Five‑minute candles around the post‑earnings move show heavy volume selling near $100 and stabilizing, but lighter, volume on the bounce. For trading, $92–93 is the critical downside pivot: a sustained hold above $93 supports tactical long entries with a first upside target near $102–103, while a decisive break below $92 opens risk to the mid‑80s.
More Breaking News
- GPN Stock Jumps As Wall Street Ups Price Targets
- GoDaddy Stock Jumps As Q3 Beat And AI Airo Fuel Bullish Outlook
- WFF Stock Plunges Then Bases As Volatility Grips Chart
- FDXF Stock Climbs As Price Action Attracts Momentum Traders
Fundamentally, Q2 was cleanly positive: EPS and revenue beats, record adjusted EBITDA margin, HSA assets up 14% to nearly $38B, and FY27 revenue and EBITDA guidance raised. The stock’s 12–14% selloff reflects disappointment with only modest guidance upside after a strong run, not a deterioration in business quality. Relative to healthcare and Healthcare Providers & Services benchmarks, HQY offers faster organic growth, superior margins, and a better balance sheet, warranting a premium multiple. With RBC reiterating Outperform and a $108 target, and with the company aggressively repurchasing stock (~$108M in Q2), I see asymmetric upside from current levels. I set a 12‑month target range of $108–115, with key support at $92 and major resistance at $106–108; accumulation is warranted on weakness above $92.
Quick Financial Overview
HealthEquity Inc. (HQY) delivered one of its strongest quarters yet. Q2 FY27 revenue grew 8% to $350.7M, slightly ahead of expectations, while net income rose 10%, confirming operating strength. The standout was a record 48% adjusted EBITDA margin, backed by AI‑enabled cost reductions and a high 70.7% gross margin, which points to strong pricing power and tight cost control.
On the balance sheet, HQY looks solid. Total revenue over the last year is about $1.31B, with revenue growing low‑teens annually over three and five years. Debt appears manageable, with total‑debt‑to‑equity at 0.48, interest coverage of 8.4, and a current ratio of 3.4, giving the company room to handle downturns. Returns on equity and assets are moderate but improving as scale builds, helped by 14% growth in HSA assets to nearly $38B.
For traders, valuation and the chart explain the harsh reaction. HQY trades at about 36x earnings and roughly 6x sales, which prices in decent growth. Weekly data show price near $105 pre‑earnings, then a gap down to the low $90s and a partial bounce toward $97. Intraday, the stock swung from about $93.6 to nearly $98 before closing off highs, showing heavy volatility and active dip‑buying but no immediate full recovery.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.